Session » Pediatric Rheumatology – ePoster III: Systemic JIA, Fever, & Vasculitis

Date: Tuesday, November 12, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2718

A Retrospective Study Comparing Refractoriness to Biologic Disease Modifying Anti-Rheumatic Drugs in Adults with Juvenile Idiopathic Arthritis as Compared to Those with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2700

Adalimumab Alone Is Superior to Adalimumab Plus Methotrexate in Juvenile Idiopathic Arthritis Associated Uveitis: Data from the ORCHIDEA Registry

9:00AM-11:00AM: Abstract Number: 2723

Alagille Syndrome and Chronic Arthritis: An International Case Series

9:00AM-11:00AM: Abstract Number: 2706

Association of Body Mass Index with Juvenile Idiopathic Arthritis Disease Activity: A Portuguese and Brazilian Collaborative Analysis with Data from Reuma.pt Registry

9:00AM-11:00AM: Abstract Number: 2725

Clinical Factors Distinguishing Between Pediatric Tumors with Arthritis at Onset and JIA: Preliminary Analysis of the ONCOREUM Study

9:00AM-11:00AM: Abstract Number: 2695

Early Treatment with Anakinra in Systemic Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2708

Effect of Immunogenicity on Efficacy and Safety of Subcutaneous or Intravenous Abatacept in Pediatric Patients with Polyarticular-Course JIA: Findings from Two Phase III Trials

9:00AM-11:00AM: Abstract Number: 2724

Farber Disease (Acid Ceramidase Deficiency): The First Natural History Study of This Rare Disease Involving Symptoms Which Can Mimic JIA

9:00AM-11:00AM: Abstract Number: 2701

Frequency of Juvenile Idiopathic Arthritis (JIA) Subgroups and JIA-associated Uveitis Among JIA Patients Admitted to Referral Pediatric Rheumatology Clinics In TurkEy: A Retrospective Study, JUPITER

9:00AM-11:00AM: Abstract Number: 2720

Implementation of an Evidence-based Transition Clinic in a Pediatric Rheumatology Academic Institution

9:00AM-11:00AM: Abstract Number: 2707

Improvement in Patient-Reported Outcomes in Patients Aged 2–5 Years with Polyarticular-Course JIA Treated with Subcutaneous Abatacept: 2-Year Results from a Phase III International Study

9:00AM-11:00AM: Abstract Number: 2715

Incidence of Juvenile Idiopathic Arthritis in the United Kingdom: Estimates from a National Primary Care Dataset

9:00AM-11:00AM: Abstract Number: 2693

Increasing Use of Biologics over Time in the First Year After Diagnosis of Systemic JIA Among Patients Enrolled in the Childhood Arthritis & Rheumatology Research Alliance (CARRA) Registry

9:00AM-11:00AM: Abstract Number: 2704

Injection Fear in Juvenile Idiopathic Arthritis Patients Using Injectable Medications

9:00AM-11:00AM: Abstract Number: 2694

Inpatient Treatment Variation in New-Onset Systemic Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2714

Investigation of Inactive Disease Activity States Among JIA Patients in the CARRA Registry

9:00AM-11:00AM: Abstract Number: 2713

Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Those with Sacroiliitis

9:00AM-11:00AM: Abstract Number: 2716

Long Term Outcomes of Childhood Onset Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2696

Long-Term Efficacy and Safety of Сanakinumab in Children with Systemic Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2717

Long-term Outcome of Juvenile-onset Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2702

Patients’ and Parents’ Perception of Disease and Its Impact on Life in Juvenile Idiopathic Arthritis: Results from Multinational Virtual Focus Groups by the OMERACT JIA Working Group

9:00AM-11:00AM: Abstract Number: 2712

Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry

9:00AM-11:00AM: Abstract Number: 2719

Predictors of Health Care Transition Practices Among North American Pediatric Rheumatology Providers

9:00AM-11:00AM: Abstract Number: 2705

Profiling Behavioral and Psychological Symptoms in Children with Spondyloarthritis and Polyarthritis

9:00AM-11:00AM: Abstract Number: 2698

Reasons for Initiation of Canakinumab of Patients with Systemic Juvenile Idiopathic Arthritis: A Retrospective Medical Chart Review from the United States

9:00AM-11:00AM: Abstract Number: 2697

Risk Score of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2710

Sarilumab, a Human Monoclonal Antibody to the Interleukin-6 Receptor, in Polyarticular-course Juvenile Idiopathic Arthritis: A 12-week, Multinational, Open-label, Dose-finding Study

9:00AM-11:00AM: Abstract Number: 2709

Secukinumab Is a Promising Treatment for Patients with Juvenile Enthesitis Related Arthritis Nonresponsive to Anti-TNF Treatment According the Juvenile Spondyloarthritis Disease Activity Index

9:00AM-11:00AM: Abstract Number: 2721

Subjective and Objective Dyscognition in Adolescents with Juvenile Fibromyalgia Syndrome

9:00AM-11:00AM: Abstract Number: 2699

Systemic Therapy in Children with Juvenile Idiopathic Arthritis-Associated Uveitis Immediately Following Failure of Methotrexate, Adalimumab and Infliximab

9:00AM-11:00AM: Abstract Number: 2703

The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Patient Characteristics, Patient Reported Outcomes and Consensus Treatment Plan Choices

9:00AM-11:00AM: Abstract Number: 2722

The down Syndrome Arthropathy Cohort in the New Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: Clinical Characteristics, Treatment and Outcomes

9:00AM-11:00AM: Abstract Number: 2711

Utilization of Biologic Treatments in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].